Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.

ABSTRACT: Protease inhibitors represent some of the most potent agents available for therapeutic strategies designed to inhibit human immunodeficiency virus type 1 (HIV-1) replication. Under certain circumstances the virus develops resistance to the inhibitor, thereby negating the benefits of this therapy. We have carried out selections for high-level resistance to each of three protease inhibitors (indinavir, ritonavir, and saquinavir) in cell culture. Mutations accumulated over most of the course of the increasing selective pressure. There was significant overlap in the identity of the mutations selected with the different inhibitors, and this gave rise to high levels of cross-resistance. Virus particles from the resistant variants all showed defects in processing at the NC/p1 protease cleavage si

SUBMITTER: Watkins T 

PROVIDER: S-EPMC151730 | biostudies-literature | 2003 Feb

REPOSITORIES: biostudies-literature